216 related articles for article (PubMed ID: 21485758)
1. Epidermal growth factor receptor targeted therapies for solid tumours.
Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
[TBL] [Abstract][Full Text] [Related]
2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
4. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
5. EGFR targeting of solid tumors.
Rocha-Lima CM; Soares HP; Raez LE; Singal R
Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Saba NF; Khuri FR; Shin DM
Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Sattler M; Abidoye O; Salgia R
ScientificWorldJournal; 2008 Sep; 8():909-19. PubMed ID: 18836658
[TBL] [Abstract][Full Text] [Related]
8. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
9. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
Tímár J; Láng I
Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
[TBL] [Abstract][Full Text] [Related]
10. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
11. EGFR antagonists in cancer treatment.
Ciardiello F; Tortora G
N Engl J Med; 2008 Mar; 358(11):1160-74. PubMed ID: 18337605
[No Abstract] [Full Text] [Related]
12. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
Okamoto I
FEBS J; 2010 Jan; 277(2):309-15. PubMed ID: 19922468
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
15. Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw PH; Adams RA
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
[TBL] [Abstract][Full Text] [Related]
16. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Cooper JB; Cohen EE
Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Marshall J
Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
